<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999125</url>
  </required_header>
  <id_info>
    <org_study_id>SudhalkarEH</org_study_id>
    <nct_id>NCT03999125</nct_id>
  </id_info>
  <brief_title>Anti-VEGF Therapy Versus Dexamethasone Implant for DME</brief_title>
  <official_title>Anti-VEGF Therapy Versus Dexamethasone Implant for Treatment Naive Diabetic Macular Edema: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sudhalkar Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sudhalkar Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We look at a randomized comparative study of 2 FDA approved anti-VEGF agents(aflibercept and
      ranibizumab) and see how they compare against the dexamethasone implant for phakic as well as
      pseudophakic eyes with treatment naive diabetic macular edema in terms of efficacy and safety
      over two years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, partially masked, observational/interventional trial looking at the efficacy
      and safety of 2 FDA approved anti-VEGF agents vis-a-vis the dexamethasone implant as primary
      therapy for treatment naive diabetic macular edema in phakic as well as pseudophakic
      patients.

      Patients with treatment naive clinically significant macular edema will be randomized to
      receive one of the aforementioned therapies in a 1:1:1 distribution. Primary inclusion
      criteria are :

      Well controlled diabetes(HbA1c&lt;7%) and co-morbidities. Central Subfield Thickness of 300
      microns or greater BCVA &lt; or equal to 6/12.

      Exclusion Criteria:

      Contraindications to the aforementioned drugs Confounding Ocular co-morbidities that can
      affect visual assessment(except Cataract Grade II or less as per the LOCS III classification)
      Refusal for enrolment

      A comprehensive ocular and systemic examination will be performed along with fundus
      fluorescein angiography, optical coherence tomography and intraocular pressure measurements
      with the Goldmann Applanation Tonometer. The BCVA will be recorded using Snellen's chart

      Intravitreal injections will be administered using a standardized technique and under strict
      asepsis. No postoperative antibiotics will be given.

      Patients will be followed on postoperative days 1, 7 and then monthly for 2 years.

      At each visit, the BCVA, IOP, ocular exam and OCT scans will be performed at each visit.

      Patients will be treated as per the guidelines laid out for the treat and extend study. For
      the dexamethasone implant, re-injections will be allowed first 3 months after the first
      injection.

      Switch therapy is permissible for anti-VEGF agents after 6 months; first to the other
      anti-VEGF(for 6 more injections) and then to the dexamethasone implant. Rescue Laser therapy
      is as per physician's description.

      Primary outcome measure: The BCVA in each group from baseline to final follow-up at 2 years.

      Secondary outcome measure: Change in CST from baseline to years, the number of injections
      required per group and the complications, if any.

      Statistical Analysis will include demographic descriptions, the Shapiro Wilk test to look for
      normality of distribution, multiple measures ANOVA test, Fisher's exact test, Chi-Square test
      and paired and unpaired t-test wherever appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2019</start_date>
  <completion_date type="Anticipated">June 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, multi-arm trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>2 years</time_frame>
    <description>BCVA measured at baseline and final follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Change in CST over 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>2 years</time_frame>
    <description>Complications in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Count</measure>
    <time_frame>2 years</time_frame>
    <description>Number of injections in each group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Clinically Significant Macular Edema Due to Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aflibercept intravitreal injection for CSME</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ranibizumab Intravitreal Injection for CSME</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone Implant for CSME</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept,</intervention_name>
    <description>Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Ranibizumab</other_name>
    <other_name>Dexamethasone Implant, Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection</intervention_name>
    <description>Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Dexamethasone Implant, Aflibercept, Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex Drug Implant Product</intervention_name>
    <description>Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Well controlled diabetes(HbA1c&lt;7%) and co-morbidities. Central Subfield Thickness of
             300 microns or greater BCVA &lt; or equal to 6/12.

        Exclusion Criteria:

          -  Contraindications to the aforementioned drugs Confounding Ocular co-morbidities that
             can affect visual assessment(except Cataract Grade II or less as per the LOCS III
             classification) Macular ischemia or proliferative Disease Refusal for enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alphavision Augenzentrum</name>
      <address>
        <city>Bremerhaven</city>
        <state>Bremen</state>
        <zip>27568</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Alper Bilgic, MS</last_name>
      <phone>+491731505937</phone>
    </contact>
    <contact_backup>
      <last_name>Aditya Sudhalkar, MS</last_name>
      <phone>+919909917561</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sudhalkar Eye Hospital</investigator_affiliation>
    <investigator_full_name>Aditya Sudhalkar</investigator_full_name>
    <investigator_title>Consultant Vitreoretinal Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All details of FFA, OCT, BCVA and IOP</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Upon completion of study</ipd_time_frame>
    <ipd_access_criteria>Will be provided only to Ophthalmologists</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

